Introduction/Background HIPEC has been evaluated in the setting of primary, interval, and recurrent surgery in patients with ovarian cancer. The objective of this systematic review was to assess complications of HIPEC in ovarian cancer surgery over two time periods.

Methodology PRISMA checklist was used to conduct this systematic review, and the protocol was registered in PROSPERO (CRD42022328928). We performed a systematic search, including Ovid/MEDLINE, Ovid/Embase, Cochrane Library, Scopus, and Web of Science databases from January 2004 to April 2022. A random-effects meta-analysis was used to generate an overall summary. Subgroup analyses were planned according to recruited period (2004–2013 and 2014–2022) for each specific complication type. Heterogeneity was assessed using the I2 statistic

Results In total, 4,928 patients were included. We evaluated 1,175 articles. Of these, 69 met criteria for inclusion (19 articles from 2004–2013 and 50 from 2014–2022). Rates of complications were as follows: blood transfusion 45%, gastrointestinal events 20%, infectious events 14%, respiratory events 12%, and urinary events 10%. No significant differences were found between the two time periods in terms of blood transfusions (33% vs 51%; p=0.46), gastrointestinal complications (15% vs 21%; p=0.36), infection (16% vs 13%; p=0.62), respiratory complications (12% vs 12%; p=0.87), urinary complications (6% vs 12%; p=0.062),or thromboembolic events (5% vs 3%; p=0.25). Similarly, no differences were found in ICU admissions (89% vs 28%; p=0.06), reoperations (8% vs 7%; p=0.50), or deaths (3% vs 3%; p=0.77).

Conclusion Overall complications have not changed over time for patients undergoing HIPEC in the setting of primary or recurrent ovarian cancer.

Disclosures Authors declare no conflicts of interest